Published in J Antimicrob Chemother on June 01, 1997
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 2.88
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother (1999) 1.63
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother (2001) 1.47
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.29
Safety of fluoroquinolones: An update. Can J Infect Dis (2002) 1.17
Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1998) 1.05
Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin. Antimicrob Agents Chemother (1999) 1.00
In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother (2001) 0.92
In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother (1998) 0.82
The new fluoroquinolones: A critical review. Can J Infect Dis (1999) 0.82
Ex vivo human placental transfer of trovafloxacin. Infect Dis Obstet Gynecol (2000) 0.81
Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase. J Pharmacol Exp Ther (2014) 0.79
Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility. Antimicrob Agents Chemother (2003) 0.78
Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. J Pharmacol Exp Ther (2014) 0.78
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis (1998) 0.77
Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother (2006) 0.76
Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. Antimicrob Agents Chemother (2000) 0.75
Factor analysis of microbiological activity data and structural parameters of antibacterial quinolones. J Mol Model (2009) 0.75
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother (1987) 3.49
Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis (1982) 2.71
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother (1995) 1.85
High-level quinolone resistance in clinical isolates of Campylobacter jejuni. J Infect Dis (1992) 1.74
Characterization of beta-lactamase induction in Enterobacter cloacae. Antimicrob Agents Chemother (1983) 1.69
Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob Agents Chemother (1989) 1.55
Development of a DNA probe for the structural gene of the 2"-O-adenyltransferase aminoglycoside-modifying enzyme. J Infect Dis (1984) 1.54
Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis (1982) 1.54
In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 1.52
Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother (1989) 1.51
Development of two DNA probes for differentiating the structural genes of subclasses I and II of the aminoglycoside-modifying enzyme 3'-aminoglycoside phosphotransferase. Antimicrob Agents Chemother (1985) 1.42
Development of resistance to cephalosporins in clinical strains of Citrobacter spp. Antimicrob Agents Chemother (1984) 1.38
Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem (1991) 1.30
Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem (1998) 1.17
Bisulfite or sulfite inhibits growth of Helicobacter pylori. J Clin Microbiol (1994) 1.13
Cloning and functional characterization of an NAD(+)-dependent DNA ligase from Staphylococcus aureus. J Bacteriol (2001) 1.11
Comparison of three DNA hybridization methods for detection of the aminoglycoside 2"-O-adenylyltransferase gene in clinical bacterial isolates. Antimicrob Agents Chemother (1985) 1.09
In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (1997) 1.07
Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob Agents Chemother (1996) 1.01
New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities. J Antibiot (Tokyo) (1998) 0.99
Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother (1992) 0.98
In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother (1990) 0.98
Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother (1993) 0.97
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry (2000) 0.96
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. J Biol Chem (1999) 0.94
Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin. Antimicrob Agents Chemother (1999) 0.92
Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Antimicrob Agents Chemother (1993) 0.91
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements. Mol Pharmacol (1995) 0.90
CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities. J Antibiot (Tokyo) (1997) 0.89
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J Med Chem (1992) 0.89
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis (1998) 0.77
Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. Antimicrob Agents Chemother (1992) 0.75